The Squamous Non-Small Cell Lung Carcinoma drugs in development market research report provides comprehensive information on the therapeutics under development for Squamous Non-Small Cell Lung Carcinoma, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses key aspects of the companies and drugs in development for Squamous Non-Small Cell Lung Carcinoma. Buy the report here.

Smarter leaders trust GlobalData

The report also covers the descriptive pharmacological action of the therapeutics and the latest news and press releases. Additionally, the report provides an overview of the key players involved in therapeutic development for Squamous Non-Small Cell Lung Carcinoma and features dormant and discontinued products.

GlobalData tracks 23 drugs in development for Squamous Non-Small Cell Lung Carcinoma by 21 companies/universities/institutes. The top development phase for Squamous Non-Small Cell Lung Carcinoma is phase ii with 12 drugs in that stage. The Squamous Non-Small Cell Lung Carcinoma pipeline has 22 drugs in development by companies and one by universities/ institutes. Some of the companies in the Squamous Non-Small Cell Lung Carcinoma pipeline products market are: AstraZeneca, GSK and First Affiliated Hospital of the University of Science and Technology of China.

The key targets in the Squamous Non-Small Cell Lung Carcinoma pipeline products market include Programmed Cell Death Protein 1 (PD1 or CD279 or PDCD1), Hepatitis A Virus Cellular Receptor 2 (T Cell Immunoglobulin And Mucin Domain Containing Protein 3 or T Cell Immunoglobulin Mucin Receptor 3 or T Cell Membrane Protein 3 or CD366 or HAVCR2), and Cells Expressing Epidermal Growth Factor Receptor (Proto Oncogene c ErbB 1 or Receptor Tyrosine Protein Kinase erbB 1 or HER1 or ERBB1 or EGFR or EC 2.7.10.1).

The key mechanisms of action in the Squamous Non-Small Cell Lung Carcinoma pipeline product include Programmed Cell Death Protein 1 (PD1 or CD279 or PDCD1) Antagonist with four drugs in Phase III. The Squamous Non-Small Cell Lung Carcinoma pipeline products include five routes of administration with the top ROA being Intravenous and nine key molecule types in the Squamous Non-Small Cell Lung Carcinoma pipeline products market including Monoclonal Antibody, and Small Molecule.

Squamous Non-Small Cell Lung Carcinoma overview

Squamous cell carcinoma (SCC) of the lung, a subtype of non-small cell lung cancer (NSCLC), typically arises centrally in the main airways like the bronchi. This cancer variant is predominantly linked to tobacco smoke, being the primary cause of cellular transformation. Smoking accounts for about 80% of lung cancer cases in men and 90% in women, with SCC showing a particularly strong association with smoking compared to other NSCLC types. Additional risk factors include age, family history, exposure to second-hand smoke, and contact with mineral dust, metal particles, or asbestos.

For a complete picture of Squamous Non-Small Cell Lung Carcinoma’s pipeline drug market, buy the report here.

Data Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s pipeline drugs offers detailed profiles of pharmaceutical drugs in all stages of pre-clinical and clinical development, from discovery through to pre-registration. Coverage is limited to novel human medicinal drugs and biosimilars seeking market approval proprietary and is one of two primary repositories of pharmaceutical drug information offered by GlobalData through its Pharmaceutical Intelligence Center.